Lung Cancer Screening and Prevention Act of 2025
Summary
HR1406 (Lung Cancer Screening and Prevention Act of 2025) would expand Medicare coverage to FDA-approved lung cancer screening tests beyond the current USPSTF-recommended set. The bill is in early committee stage with no authorized funding, limiting near-term market impact. GEHC, LH, and DGX are structural beneficiaries if passed, but passage is uncertain and distant.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR1406 is early-stage legislation with no funding authorized and no legislative progress in 14 months
- 2.Passage would structurally benefit GEHC (imaging equipment), LH and DGX (clinical lab testing) through increased Medicare screening volumes
- 3.Near-term market impact is negligible; the bill faces an uncertain path through two House committees and both chambers
Market Implications
No near-term market implications from this bill given its stalled committee status. However, investors should monitor GEHC, LH, and DGX for structural upside if the bill gains momentum. GEHC's recent 15.72% monthly decline to $59.99 (near its 52-week low of $58.75) is unrelated to this legislation and may present a risk/reward consideration for exposure to diagnostic imaging, but the bill itself does not justify action today. LH at $260.32 and DGX at $192.87 have been relatively stable over the same period.
Full Analysis
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
Some confirming evidence found across public data sources
What the bill does
Regulatory expansion of Medicare coverage to FDA-approved lung cancer screening tests beyond current USPSTF recommendations, via CMS national coverage determination process
Who must act
Centers for Medicare & Medicaid Services (CMS)
What happens
CMS must set coverage and payment limits for additional lung cancer screening tests; screening volumes for diagnostic imaging and lab testing increase as Medicare beneficiaries gain access to a broader set of FDA-cleared tests
Stock impact
GEHC's diagnostic imaging segment (CT, PET, digital X-ray) supplies equipment used in lung cancer screening; increased screening volumes drive demand for imaging hardware, service contracts, and consumables. Imaging equipment is GEHC's primary revenue segment.
What the bill does
Regulatory expansion of Medicare coverage to FDA-approved lung cancer screening tests beyond current USPSTF recommendations, via CMS national coverage determination process
Who must act
Centers for Medicare & Medicaid Services (CMS)
What happens
CMS must set coverage and payment limits for additional lung cancer screening tests; screening volumes for diagnostic imaging and lab testing increase as Medicare beneficiaries gain access to a broader set of FDA-cleared tests
Stock impact
Labcorp's diagnostic testing services include lab-based lung cancer screening tests; increased Medicare-covered screening volumes boost testing revenue. Labcorp operates one of the two largest US clinical lab networks alongside DGX.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
SUPPORT for Patients and Communities Reauthorization Act of 2025
ASAP Act
CHOICE for Veterans Act of 2025
Increasing Access to Lung Cancer Screening Act
Reducing Hereditary Cancer Act
Access to Breast Cancer Diagnosis Act of 2025
Supporting Healthy Moms and Babies Act
Thyroid Disease CARE Act of 2025
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Promoting Efficiency, Accountability, and Performance in Federal Contracting
This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.
Accelerating Medical Treatments for Serious Mental Illness
This executive order directs the FDA to prioritize review and facilitate 'Right to Try' access for psychedelic drugs, including ibogaine compounds, that have received Breakthrough Therapy designation for serious mental illnesses. It also allocates $50 million from HHS to support state programs advancing these treatments and mandates collaboration between HHS, FDA, VA, and the private sector to increase clinical trial participation and data sharing for these drugs. The Attorney General is further directed to expedite rescheduling reviews for approved Schedule I psychedelic substances.